GoodRx (NASDAQ:GDRX) Posts Earnings Results, Meets Estimates

GoodRx (NASDAQ:GDRX) posted its earnings results on Wednesday. The company reported $0.09 earnings per share for the quarter, meeting the consensus estimate of $0.09, FiscalAI reports. GoodRx had a net margin of 3.97% and a return on equity of 9.73%. The business had revenue of $194.79 million for the quarter, compared to analyst estimates of $193.27 million. During the same quarter in the previous year, the business posted $0.09 EPS. The business’s quarterly revenue was down 1.9% on a year-over-year basis.

GoodRx Stock Performance

NASDAQ GDRX traded down $0.45 on Thursday, hitting $2.01. The stock had a trading volume of 5,812,351 shares, compared to its average volume of 2,994,122. The company’s 50-day moving average is $2.54 and its two-hundred day moving average is $3.28. GoodRx has a one year low of $1.92 and a one year high of $5.81. The stock has a market cap of $680.56 million, a price-to-earnings ratio of 22.28, a P/E/G ratio of 0.90 and a beta of 1.50. The company has a quick ratio of 3.11, a current ratio of 3.11 and a debt-to-equity ratio of 0.81.

Institutional Trading of GoodRx

Several large investors have recently added to or reduced their stakes in the business. Virtu Financial LLC grew its stake in shares of GoodRx by 903.3% in the fourth quarter. Virtu Financial LLC now owns 133,886 shares of the company’s stock worth $363,000 after purchasing an additional 120,542 shares in the last quarter. Invesco Ltd. lifted its holdings in GoodRx by 48.8% in the fourth quarter. Invesco Ltd. now owns 186,534 shares of the company’s stock worth $506,000 after purchasing an additional 61,193 shares during the period. Mercer Global Advisors Inc. ADV bought a new position in GoodRx in the 4th quarter valued at about $51,000. EP Wealth Advisors LLC acquired a new position in GoodRx during the 4th quarter valued at about $44,000. Finally, Mackenzie Financial Corp bought a new stake in shares of GoodRx during the 4th quarter worth about $1,009,000. 63.77% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Citigroup lowered their target price on GoodRx from $5.00 to $4.50 and set a “buy” rating for the company in a research note on Friday, January 9th. Wall Street Zen cut shares of GoodRx from a “buy” rating to a “hold” rating in a research report on Sunday, January 25th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of GoodRx in a report on Tuesday, December 23rd. Jefferies Financial Group lowered shares of GoodRx to a “hold” rating in a report on Thursday, January 22nd. Finally, TD Cowen decreased their price objective on shares of GoodRx from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Monday, November 10th. Five equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, GoodRx currently has a consensus rating of “Hold” and a consensus price target of $4.73.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.